[14]Although third-generation aromatase inhibitors and cytotoxic drugs, such as taxanes, have been approved by the Food and Drug Administration (FDA) to treat early breast cancer since 2005 and 2006, respectively,[15] there were more anthracycline-based adjuvant regimens (rather than CMF),more standard use of Tamoxifen, and an increasingly individualized treatment approach for metastatic disease in C2. Here, CYP19A1 is linked to metastatic neoplasm.